Edition:
United States

Mesoblast Ltd (MESO.OQ)

MESO.OQ on NASDAQ Stock Exchange Global Select Market

4.25USD
14 Dec 2018
Change (% chg)

$-0.24 (-5.35%)
Prev Close
$4.49
Open
$4.38
Day's High
$4.38
Day's Low
$4.12
Volume
7,038
Avg. Vol
15,343
52-wk High
$8.74
52-wk Low
$4.00

Latest Key Developments (Source: Significant Developments)

Mesoblast Says Meetings Held With FDA Support Planned Regulatory Filing For Remestemcel-L
Thursday, 13 Dec 2018 06:00am EST 

Dec 13 (Reuters) - Mesoblast Ltd ::MEETINGS HELD WITH FDA SUPPORT MESOBLAST’S PLANNED REGULATORY FILING FOR COMMERCIALIZATION OF REMESTEMCEL-L IN ACUTE GVHD.MESOBLAST LTD - MESOBLAST GAINED AGREEMENT FROM FDA ON PROPOSED CHEMISTRY AND MANUFACTURING FOR COMMERCIALIZATION..MESOBLAST LTD - FDA ALSO PROVIDED GUIDANCE ON PRESENTATION OF DATA FROM COMPLETED 55-PATIENT PHASE 3 TRIAL.MESOBLAST LTD - PLANS TO INITIATE SUBMISSION OF BLA WITH FDA IN EARLY 2019 FOR USE OF REMESTEMCEL-L IN TREATING AGVHD IN CHILDREN.MESOBLAST LTD - FDA ALSO PROVIDED GUIDANCE FOR 241-PATIENT EXPANDED ACCESS PROGRAM TO BE INCLUDED IN FILING FOR PROPOSED INDICATION.  Full Article

Mesoblast Says Meetings Held With FDA Support MSB's Planned GVHD Filing
Wednesday, 12 Dec 2018 07:32pm EST 

Dec 13 (Reuters) - Mesoblast Ltd ::GAINED AGREEMENT FROM FDA ON PROPOSED CHEMISTRY AND MANUFACTURING FOR COMMERCIALIZATION OF REMESTEMCEL-L IN PEDIATRIC PATIENTS.IN PHASE 3 TRIAL, CO MET PRE-SPECIFIED PRIMARY ENDPOINT OF IMPROVED DAY 28 OVERALL RESPONSE AND IMPROVED RESPONDER SURVIVAL THROUGH DAY 180.PLANS TO INITIATE SUBMISSION OF BLA WITH FDA IN EARLY 2019 FOR USE OF REMESTEMCEL-L IN TREATING AGVHD IN CHILDREN.  Full Article

Mesoblast Ltd Says Qtrly Loss Attributable $19.5 Mln
Thursday, 15 Nov 2018 06:24pm EST 

Nov 16 (Reuters) - Mesoblast Ltd ::QTRLY LOSS ATTRIBUTABLE $19.5 MILLION VERSUS LOSS OF $7.0 MILLION.QTRLY REVENUE $11.6 MILLION VERSUS $1.2 MILLION."ANTICIPATE THAT WE MAY CONTINUE TO INCUR SIGNIFICANT LOSSES FOR FORESEEABLE FUTURE".ANTICIPATE THAT COMBINED WORLDWIDE TURNOVER OF MESOBLAST GROUP WILL BE IN EXCESS OF A$20.0 MILLION FOR FY ENDED JUNE 2019.  Full Article

Mesoblast Expands Partnership With JCR Pharmaceuticals
Tuesday, 23 Oct 2018 06:40pm EDT 

Oct 24 (Reuters) - Mesoblast Ltd ::EXPANDS PARTNERSHIP WITH JCR PHARMACEUTICALS FOR TREATMENT OF WOUND HEALING IN EPIDERMOLYSIS BULLOSA.  Full Article

Mesoblast Says FY Loss Attributable To Owners Of Mesoblast $35.3 Mln
Wednesday, 29 Aug 2018 05:37pm EDT 

Aug 30 (Reuters) - Mesoblast Ltd ::FY LOSS ATTRIBUTABLE TO THE OWNERS OF MESOBLAST LIMITED $35.3 MILLION VERSUS LOSS $76.8 MILLION.FY TOTAL REVENUE $17.3 MILLION VERSUS $2.4 MILLION.SUBJECT TO ACHIEVING CERTAIN MILESTONES,ADDITIONAL $50 MILLION MAY BE AVAILABLE UNDER EXISTING ARRANGEMENTS WITH HERCULES CAPITAL & NOVAQUEST.  Full Article

Mesoblast Ltd Enters Alliance With Tasly Pharmaceutical Group
Tuesday, 17 Jul 2018 05:43am EDT 

July 17 (Reuters) - Mesoblast Ltd ::ENTERED INTO A STRATEGIC ALLIANCE WITH TASLY PHARMACEUTICAL GROUP.DEAL FOR DEVELOPMENT IN CHINA OF CO'S PRODUCT FOR TREATMENT OR PREVENTION OF CHRONIC HEART FAILURE AND ACUTE MYOCARDIAL INFARCTION.UNDER ALLIANCE, MESOBLAST WILL RECEIVE US$40 MILLION ON CLOSING.  Full Article

Mesoblast Ltd Says Enters US$50 Mln Financing With Novaquest Capital
Sunday, 1 Jul 2018 07:44pm EDT 

July 2 (Reuters) - Mesoblast Ltd ::ENTERS US$50 MILLION FINANCING WITH NOVAQUEST CAPITAL FOR REMESTEMCEL-L IN TREATMENT OF ACUTE GRAFT VERSUS HOST DISEASE.NOVAQUEST WILL PROVIDE A NON-DILUTIVE US$40 MILLION, EIGHT-YEAR TERM LOAN AND PURCHASE US$10 MILLION OF MESOBLAST COMMON SHARES.  Full Article

Mesoblast Appoints Josh Muntner As Its New CFO
Wednesday, 30 May 2018 06:41pm EDT 

May 31 (Reuters) - Mesoblast Ltd ::APPOINTS JOSH MUNTNER AS ITS NEW CHIEF FINANCIAL OFFICER.MUNTNER TO REPLACE PAUL HODGKINSON.  Full Article

Mesoblast Posts Qtrly Loss Attributable $21.1 Million
Wednesday, 30 May 2018 05:52pm EDT 

May 31 (Reuters) - Mesoblast Ltd ::QTRLY REVENUE $1.1 MILLION VERSUS $901,000 .QTRLY LOSS ATTRIBUTABLE $21.1 MILLION VERSUS LOSS $9.8 MILLION."THERE IS UNCERTAINTY RELATED TO GROUP'S ABILITY TO PARTNER PROGRAMS, RAISE CAPITAL OR DEBT AT TERMS TO MEET GROUP'S REQUIREMENTS".THERE IS UNCERTAINTY RELATED TO CO'S ABILITY TO SUSTAINABLY MAINTAIN IMPLEMENTED COST REDUCTIONS AND FURTHER DEFER PROGRAMS ON TIMELY BASIS.  Full Article

Mesoblast To Develop Cell-Based Immunotherapies For Solid Cancers With Cartherics
Monday, 28 May 2018 08:00pm EDT 

May 29 (Reuters) - Mesoblast Ltd ::PARTNERS WITH CARTHERICS TO DEVELOP 'OFF-THE-SHELF' CELL-BASED IMMUNOTHERAPIES FOR SOLID CANCERS.PROGRAM WILL BE FUNDED BY A$12.6 MILLION FROM COLLABORATORS IN AUSTRALIAN GOVERNMENT'S COOPERATIVE RESEARCH CENTRES PROGRAM.  Full Article